Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Similarity of Bevacizumab (New vs Old Manufacturing Process) in Healthy Males
NCT05005455Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jul 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bevacizumab in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), glioblastoma (GBM) and 1 more (2 arms), sponsored by Innovent Biologics. Primary endpoint: Area Under the Curve from time zero to infinity at 84 days. Started Jul 2021; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)glioblastoma (GBM)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05005455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005455.